Study finds African Americans with cancer at higher risk for blood clots

byBoston University School of MedicineCredit: CC0 Public DomainAfrican-Americans are at higher risk for cancer-associated venous thromboembolism (VTE) as compared with patients from other races.

Updated on: December 22,2023

Study finds African Americans with cancer at higher risk for blood clots

byBoston University School of MedicineCredit: CC0 Public DomainAfrican-Americans are at higher risk for cancer-associated venous thromboembolism (VTE) as compared with patients from other races.

Updated on:December 22,2023

Genetic analysis of the most common type of bladder cancer yields guidance on treatment options

byUNC Lineberger Comprehensive Cancer CenterUC-GENOME study design and molecular subtyping shows enrichment of Stroma-rich primary tumors in metastatic datasets. Credit:Nature Communicatio

Updated on: December 21,2023

Genetic analysis of the most common type of bladder cancer yields guidance on treatment options

byUNC Lineberger Comprehensive Cancer CenterUC-GENOME study design and molecular subtyping shows enrichment of Stroma-rich primary tumors in metastatic datasets. Credit:Nature Communicatio

Updated on:December 21,2023

Measuring 'quality of life' is an important trend in cancer care

byUniversity of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainAs novel cancer treatments continually emerge, it is essential to collect data on patients' quality of life along wit

Updated on: August 27,2024

Measuring 'quality of life' is an important trend in cancer care

byUniversity of Rochester Medical CenterCredit: Pixabay/CC0 Public DomainAs novel cancer treatments continually emerge, it is essential to collect data on patients' quality of life along wit

Updated on:August 27,2024

Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas

The PD-1 inhibitor pembrolizumab (Keytruda) displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes, according to findings from the phase 2 A

Updated on: November 07,2023

Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas

The PD-1 inhibitor pembrolizumab (Keytruda) displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes, according to findings from the phase 2 A

Updated on:November 07,2023

Oral paclitaxel yields better outcomes than intravenous paclitaxel for metastatic breast cancer

byAmerican Association for Cancer ResearchCredit: CC0 Public DomainMetastatic breast cancer patients who received an oral formulation of the chemotherapy drug paclitaxel had better response and

Updated on: December 22,2023

Oral paclitaxel yields better outcomes than intravenous paclitaxel for metastatic breast cancer

byAmerican Association for Cancer ResearchCredit: CC0 Public DomainMetastatic breast cancer patients who received an oral formulation of the chemotherapy drug paclitaxel had better response and

Updated on:December 22,2023

Researching a new treatment option for severe blood disorders of the bone marrow

by Anne Grimm,Leipzig UniversityCredit: CC0 Public DomainWhen people develop myelodysplastic neoplasms (MDS), the healthy maturation of blood cells is impaired. Severe forms, known as higher-ris

Updated on: March 21,2024

Researching a new treatment option for severe blood disorders of the bone marrow

by Anne Grimm,Leipzig UniversityCredit: CC0 Public DomainWhen people develop myelodysplastic neoplasms (MDS), the healthy maturation of blood cells is impaired. Severe forms, known as higher-ris

Updated on:March 21,2024

Novel drug shows promising efficacy for patients with multiple myeloma

by Jenny Owen,Emory UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDResults of an international clin

Updated on: December 18,2023

Novel drug shows promising efficacy for patients with multiple myeloma

by Jenny Owen,Emory UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDResults of an international clin

Updated on:December 18,2023

Localizing BRCA gene mutations to better treat ovarian cancer

byUniversity of GenevaDistribution of mutations in BRCA1 and BRCA2. A. Graphical summary of BRCA1 and BRCA2 mutations. Mutation plot was generated using cBioPortal MutationMapper tool. Black = n

Updated on: December 20,2023

Localizing BRCA gene mutations to better treat ovarian cancer

byUniversity of GenevaDistribution of mutations in BRCA1 and BRCA2. A. Graphical summary of BRCA1 and BRCA2 mutations. Mutation plot was generated using cBioPortal MutationMapper tool. Black = n

Updated on:December 20,2023

Mapping oesophageal cancer genes leads to new drug targets

byCancer Research UK| News4 February 2019Mutations that cause oesophageal adenocarcinoma (OAC) have been mapped in unprecedented detail – unveiling that more than half could be targeted by

Updated on: December 19,2023

Mapping oesophageal cancer genes leads to new drug targets

byCancer Research UK| News4 February 2019Mutations that cause oesophageal adenocarcinoma (OAC) have been mapped in unprecedented detail – unveiling that more than half could be targeted by

Updated on:December 19,2023

FastGlioma: The AI Model Transforming Glioma Surgery

Powered by artificial intelligence (AI), FastGlioma offers a new level of precision and efficiency in tumor detection, holding the potential to revolutionize glioma surgery.

Updated on: November 22,2024

FastGlioma: The AI Model Transforming Glioma Surgery

Powered by artificial intelligence (AI), FastGlioma offers a new level of precision and efficiency in tumor detection, holding the potential to revolutionize glioma surgery.

Updated on:November 22,2024

First test of anti-cancer agent PAC-1 in human clinical trials shows promise

by Diana Yates,University of Illinois at Urbana-ChampaignProcaspase-3 (PC-3) expressions in diverse tumor histologies categorized as moderate-to-strong immunostaining intensities. Credit:B

Updated on: December 27,2023

First test of anti-cancer agent PAC-1 in human clinical trials shows promise

by Diana Yates,University of Illinois at Urbana-ChampaignProcaspase-3 (PC-3) expressions in diverse tumor histologies categorized as moderate-to-strong immunostaining intensities. Credit:B

Updated on:December 27,2023

What Is B-Cell Lymphoma?

What Is B-Cell Lymphoma?ByCorey WhelanPublished on February 23, 2022Medically reviewed byGagandeep Brar, MDB-cell lymphoma is a type ofnon-Hodgkin's lymphoma (NHL). N

Updated on: January 28,2024

What Is B-Cell Lymphoma?

What Is B-Cell Lymphoma?ByCorey WhelanPublished on February 23, 2022Medically reviewed byGagandeep Brar, MDB-cell lymphoma is a type ofnon-Hodgkin's lymphoma (NHL). N

Updated on:January 28,2024